miRecule
Gaithersburg
About miRecule
miRecule™ is a biotechnology company developing Antibody RNA Conjugate (ARC) therapies for cancer and muscular dystrophy. Our approach to drug design revolves around using genomic patient data to create highly tailored therapeutics designed to help patients live a life free from the debilitating symptoms of their disorders. Our proprietary DREAmiR™ platform utilizes genomic and outcome data from thousands of patients to identify underlying genetic changes that cause their disease, and then creates a novel RNA therapeutic that can directly target and fix that genetic abnormality. miRecule is currently applying the DREAmiR™ platform to develop first-in-class therapies, with lead programs in Head & Neck Cancer and Facioscapulohumeral Muscular Dystrophy.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $7.2M
- Funding stage: Seed
- Last round: Seed (May 2021)
- Website: mirecule.com
Industries & Categories
Biopharma, Biotechnology, Health Care
Social Profiles
Canonical: https://fsome.com/organization/mirecule-66765 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.